Status:
COMPLETED
Glybera Registry, Lipoprotein Lipase Deficient (LPLD) Patients
Lead Sponsor:
UniQure Biopharma B.V.
Conditions:
Lipoprotein Lipase Deficiency
Familial Hyperlipoproteinemia Type 1
Eligibility:
All Genders
Brief Summary
Lipoprotein lipase deficiency (LPLD) is a rare autosomal recessive disorder, characterized by loss-of function mutations in the LPL gene, leading to the inability to produce functionally active lipopr...
Detailed Description
All patients treated with GLYBERA®, in a clinical trial and when GLYBERA® was commercially available who are currently participating in the LPLD Registry (Long term follow up of safety and efficacy in...
Eligibility Criteria
Inclusion
- All patients treated with GLYBERA®, either during their participation in a clinical trial or in the commercial setting till October 25th, 2017 (= expiration date of Marketing Authorization of GLYBERA®), and
- Who are currently participating in the LPLD Registry
Exclusion
- None
Key Trial Info
Start Date :
June 27 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03293810
Start Date
June 27 2014
End Date
June 1 2023
Last Update
November 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Interdisciplinary Metabolism Center, Lipid Out-Patient-Clinic, Lipid Apheresis, Charité, University of Berlin
Berlin, Germany, 13353